Germany - Drugs

Description

The participating health insurance funds are pursuing the goal of concluding rebate contracts with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V for the active ingredient Clostridium botulinum toxin type A (finished drug name: Dysport(R)). The contract will be concluded within the framework of the open-house biologics procedure of the participating health insurance funds: individual negotiations on the content of the contract will not be conducted; uniform conditions will apply. The participating health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months starting on 01.05.2022. The contract ends on 30.04.2024 at the latest, irrespective of the date on which the contract was concluded. All further information can be found in the participation and contract documents.
Due to the existence of industrial property rights with regard to the active ingredient covered by the agreement, the participation and contract documents will only be made available to pharmaceutical companies that offer/market medicinal products containing the active ingredient covered by the agreement or that can credibly demonstrate to TK that they offer/market medicinal products containing the active ingredient covered by the agreement. A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of marketing authorization and company) and confirm this in electronic form in accordance with Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is associated with any submission to public procurement regulations, the application of which is not prescribed by law or by public procurement regulations.

Opportunity closing date

30 April 2024

Value of contract

to be confirmed